{
  "schema_version": "1.0",
  "type": "article",
  "title": "AZ 的 AI 大單只先付 3%，人體數據才值錢",
  "url": "https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront.html",
  "markdown_url": "https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront.md",
  "lang": "zh-Hant",
  "date": "2026-10-21",
  "publish_at": "2026-10-21T08:00:00+08:00",
  "updated_at": "2026-10-21",
  "category": "商業分析系列",
  "topic": "商業分析系列",
  "tags": [
    "AstraZeneca",
    "insitro",
    "AI 新藥",
    "Isomorphic Labs",
    "MASH"
  ],
  "summary": "10 月 15 日，AstraZeneca 和 insitro 簽下最高 15 億美元的 AI 合約，簽約先付只有 4,000 萬。五筆 AI 大單先付都在 1% 到 3%，武田買一支有二期數據的藥，先付 40 億。標靶是門票，人體數據才是籌碼。",
  "key_points": [
    "AstraZeneca 在 2026 年 10 月 15 日與 insitro 簽下 MASH 與心肌病的 AI 標靶合作，簽約先付 4,000 萬美元、里程碑最高約 14.6 億美元，另有個位數權利金；先付只占約 15 億美元總額的 2.7%。",
    "五筆 AI 新藥交易的先付比例都在 1% 到 3%：Lilly × Isomorphic Labs 2.6%、Novartis × Isomorphic Labs 3.0%（2024 年 1 月）、AZ × 石藥集團 2.1%（2025 年 6 月）、Roche × Recursion 1.25%（2021 年 12 月）。",
    "對照組是武田 2023 年 2 月買下已有二期 b 數據的 TYK2 抑制劑 TAK-279，先付約 40 億美元、約占總額 67%，是 AZ 付給 insitro 先付款的 100 倍；insitro 自己的肝臟計畫預計 2027 年初進入人體試驗。"
  ],
  "facts": [
    {
      "claim": "AstraZeneca × insitro 簽約先付（2026-10-15 簽約）",
      "value": 40,
      "unit": "百萬美元",
      "as_of": "2026-10-15",
      "source": "https://live.euronext.com/en/financial-news/astrazeneca-strikes-40-million-ai-drug-discovery-deal-insitro"
    },
    {
      "claim": "AstraZeneca × insitro 里程碑上限",
      "value": 1.46,
      "unit": "十億美元",
      "as_of": "2026-10-15",
      "source": "https://live.euronext.com/en/financial-news/astrazeneca-strikes-40-million-ai-drug-discovery-deal-insitro"
    },
    {
      "claim": "AstraZeneca × insitro 交易總額上限",
      "value": 1.5,
      "unit": "十億美元",
      "as_of": "2026-10-15",
      "source": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "claim": "AstraZeneca × insitro 權利金級距",
      "value": "個位數",
      "unit": "%",
      "as_of": "2026-10-15",
      "source": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "claim": "AstraZeneca × insitro 先付占總額比例（4,000 萬／約 15 億）",
      "value": 2.7,
      "unit": "%",
      "as_of": "2026-10-15",
      "source": "https://qz.com/astrazeneca-insitro-ai-drug-discovery-liver-heart-101526"
    },
    {
      "claim": "Daphne Koller 在史丹佛任教年數",
      "value": 18,
      "unit": "年",
      "as_of": "2026-10-15",
      "source": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "claim": "Gilead × insitro NASH 合作先付（2019）",
      "value": 15,
      "unit": "百萬美元",
      "as_of": "2019-04-16",
      "source": "https://www.gilead.com/news/news-details/2019/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis"
    },
    {
      "claim": "Gilead × insitro 2019 年合作權利金級距",
      "value": "低雙位數",
      "unit": "%",
      "as_of": "2019-04-16",
      "source": "https://www.gilead.com/news/news-details/2019/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis"
    },
    {
      "claim": "insitro C 輪募資",
      "value": 400,
      "unit": "百萬美元",
      "as_of": "2021-03-15",
      "source": "https://www.insitro.com/news/insitro-raises-400-million-in-series-c-financing"
    },
    {
      "claim": "insitro 累計募資",
      "value": "超過 750",
      "unit": "百萬美元",
      "as_of": "2026-09-08",
      "source": "https://www.citybiz.co/article/899596/insitro-names-hideo-makimura-chief-medical-officer-ahead-of-first-clinical-trials/"
    },
    {
      "claim": "insitro 2025 年 5 月裁員比例",
      "value": 22,
      "unit": "%",
      "as_of": "2025-05-09",
      "source": "https://www.biospace.com/job-trends/insitro-cuts-22-of-workforce-extending-runway-into-2027"
    },
    {
      "claim": "insitro 最前面的肝臟計畫預計進入人體試驗時間",
      "value": "2027 年初",
      "unit": "時間",
      "as_of": "2026-09-08",
      "source": "https://www.citybiz.co/article/899596/insitro-names-hideo-makimura-chief-medical-officer-ahead-of-first-clinical-trials/"
    },
    {
      "claim": "Rezdiffra 2026 年第二季淨銷售",
      "value": 364.3,
      "unit": "百萬美元",
      "as_of": "2026-07-30",
      "source": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "claim": "Rezdiffra 2026 年第二季淨銷售年增率",
      "value": 71,
      "unit": "%",
      "as_of": "2026-07-30",
      "source": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "claim": "Rezdiffra 2026 年 6 月 30 日使用病人數",
      "value": "超過 49,000",
      "unit": "人",
      "as_of": "2026-06-30",
      "source": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "claim": "Wegovy 獲 FDA 加速核准治療非肝硬化 MASH 日期",
      "value": "2025-08-15",
      "unit": "日期",
      "as_of": "2025-08-15",
      "source": "https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash"
    },
    {
      "claim": "Lilly × Isomorphic Labs 先付",
      "value": 45,
      "unit": "百萬美元",
      "as_of": "2024-01-07",
      "source": "https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery"
    },
    {
      "claim": "Novartis × Isomorphic Labs 先付",
      "value": 37.5,
      "unit": "百萬美元",
      "as_of": "2024-01-07",
      "source": "https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery"
    },
    {
      "claim": "Roche/Genentech × Recursion 先付",
      "value": 150,
      "unit": "百萬美元",
      "as_of": "2021-12-07",
      "source": "https://genengnews.com/news/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort"
    },
    {
      "claim": "Roche/Genentech × Recursion 總額上限",
      "value": 12,
      "unit": "十億美元",
      "as_of": "2021-12-07",
      "source": "https://genengnews.com/news/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort"
    },
    {
      "claim": "AstraZeneca × 石藥集團先付",
      "value": 110,
      "unit": "百萬美元",
      "as_of": "2025-06-13",
      "source": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html"
    },
    {
      "claim": "AstraZeneca × 石藥集團總額（先付＋開發 16.2 億＋銷售 36 億）",
      "value": 5.33,
      "unit": "十億美元",
      "as_of": "2025-06-13",
      "source": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html"
    },
    {
      "claim": "武田收購 Nimbus TYK2 子公司先付",
      "value": 4,
      "unit": "十億美元",
      "as_of": "2023-02-08",
      "source": "https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/"
    },
    {
      "claim": "武田 × Nimbus 先付占總額比例（40 億／60 億）",
      "value": 67,
      "unit": "%",
      "as_of": "2023-02-08",
      "source": "https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/"
    }
  ],
  "sections": [
    "01｜15 億美元的頭條，簽約只付 4,000 萬",
    "02｜AZ 要買的，是肝臟裡還沒人按過的開關",
    "03｜五筆 AI 大單，先付全卡在 1% 到 3%",
    "04｜有人體數據，先付跳到 100 倍",
    "05｜台灣的授權新聞，也該用這把尺量",
    "參考資料"
  ],
  "references": [
    {
      "title": "AstraZeneca strikes $40 million AI drug discovery deal with insitro（Reuters",
      "source": "Euronext",
      "date": "2026-10-15",
      "url": "https://live.euronext.com/en/financial-news/astrazeneca-strikes-40-million-ai-drug-discovery-deal-insitro"
    },
    {
      "title": "AstraZeneca signs AI drug discovery deal with insitro",
      "source": "Quartz",
      "date": "2026-10-15",
      "url": "https://qz.com/astrazeneca-insitro-ai-drug-discovery-liver-heart-101526"
    },
    {
      "title": "Insitro's Virtual Human attracts $1.5B MASH deal with Astrazeneca",
      "source": "BioWorld",
      "date": "2026-10-15",
      "url": "https://www.bioworld.com/articles/734729-insitros-virtual-human-attracts-15b-mash-deal-with-astrazeneca"
    },
    {
      "title": "Daphne Koller",
      "source": "Wikipedia",
      "date": "2026-10-17",
      "url": "https://en.wikipedia.org/wiki/Daphne_Koller"
    },
    {
      "title": "Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis",
      "source": "Gilead",
      "date": "2019-04-16",
      "url": "https://www.gilead.com/news/news-details/2019/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis"
    },
    {
      "title": "insitro Raises $400 Million in Series C Financing",
      "source": "insitro",
      "date": "2021-03-15",
      "url": "https://www.insitro.com/news/insitro-raises-400-million-in-series-c-financing"
    },
    {
      "title": "Insitro Cuts 22% of Workforce, Extending Runway Into 2027",
      "source": "BioSpace",
      "date": "2025-05-09",
      "url": "https://www.biospace.com/job-trends/insitro-cuts-22-of-workforce-extending-runway-into-2027"
    },
    {
      "title": "insitro Names Hideo Makimura Chief Medical Officer Ahead of First Clinical Trials",
      "source": "citybiz",
      "date": "2026-09-08",
      "url": "https://www.citybiz.co/article/899596/insitro-names-hideo-makimura-chief-medical-officer-ahead-of-first-clinical-trials/"
    },
    {
      "title": "Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results",
      "source": "Madrigal（SEC 8-K",
      "date": "2026-07-30",
      "url": "https://www.sec.gov/Archives/edgar/data/0001157601/000162828026050775/exhibit991-63026earningspr.htm"
    },
    {
      "title": "FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH",
      "source": "HCPLive",
      "date": "2025-08-15",
      "url": "https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash"
    },
    {
      "title": "Isomorphic inks deals with Eli Lilly and Novartis for drug discovery",
      "source": "TechCrunch",
      "date": "2024-01-07",
      "url": "https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery"
    },
    {
      "title": "Roche, Genentech, Recursion Launch Up-to-$12B AI Drug Discovery Effort",
      "source": "GEN",
      "date": "2021-12-07",
      "url": "https://genengnews.com/news/roche-genentech-recursion-launch-up-to-12b-ai-drug-discovery-effort"
    },
    {
      "title": "AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research",
      "source": "AstraZeneca",
      "date": "2025-06-13",
      "url": "https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-enters-into-collaboration-with-cspc.html"
    },
    {
      "title": "Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary",
      "source": "Takeda",
      "date": "2023-02-08",
      "url": "https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary/"
    }
  ],
  "images": [
    {
      "alt": "圖1｜Rezdiffra、Wegovy 打已知的開關，insitro 替 AZ 找下一個",
      "url": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront/figure-01.png"
    },
    {
      "alt": "圖2｜五筆 AI 新藥交易，先付都只占總額 1% 到 3%",
      "url": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront/figure-02.png"
    },
    {
      "alt": "圖3｜同樣是先付，有人體數據的分子拿到 100 倍",
      "url": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront/figure-03.png"
    }
  ],
  "cover_image": "https://drugnews.com.tw/assets/articles/astrazeneca-insitro-ai-deal-upfront/cover.png",
  "publisher": {
    "name": "Drugnews｜藥時事",
    "url": "https://drugnews.com.tw/",
    "profile": "https://drugnews.com.tw/brand-profile.json"
  },
  "citation": "Drugnews｜藥時事（2026-10-21）。AZ 的 AI 大單只先付 3%，人體數據才值錢。https://drugnews.com.tw/articles/2026-10-21-astrazeneca-insitro-ai-deal-upfront.html",
  "disclaimer": "本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。",
  "translations": {}
}